|
|
|
|
VASOTEC® (enalapril maleate) is indicated for the treatment of
hypertension, symptomatic congestive heart failure, and asymptomatic left
ventricular dysfunction. VASOTEC® is the maleate salt of enalapril, the ethyl
ester of a long-acting angiotensin converting enzyme inhibitor, enalaprilat.
Enalapril is a pro-drug; following oral administration, it is bioactivated by
hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin
converting enzyme inhibitor. Enalapril maleate is supplied as 2.5mg, 5mg, 10mg,
and 20mg doses for oral administration.
Effective March 1, 2007, there was a change in the appearance to the tablets for VASOTEC®. There is no change to the medication in the tablets. USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, VASOTEC® should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality. For important information about VASOTEC®, please see Prescribing Information. Product information on this page is intended for U.S. health practitioners only. Patients and Canadian health practitioners should return to the User Profile Selection page and select accordingly. If you have medical information questions or need to report an adverse event or product complaint, please contact the Biovail Medical Communications Center at 1-866-BIOVAIL (246-8245), option 3 by phone, or (908) 927-1850 by fax, or Email Med.Comm@BIOVAIL.com |
|
|
|||||||||||||||
|
|
|
|
|||||||||||||||||
| © 2007 Biovail Corporation - All Rights Reserved (BIO113B0602) | Privacy Policy | Disclaimers |
